A Randomized, Combined SAD/MAD Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of AST 008 in Healthy Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs AST 008 (Primary)
- Indications Atopic dermatitis; Brain cancer; Cancer; Epidermolysis bullosa; Eye-Disorders; Fibrosis; Gastrointestinal disorders; Inflammation; Lymphoma; Respiration disorders; Skin disorders; Solid tumours; Transplant rejection
- Focus Adverse reactions
- Sponsors Exicure
- 14 Nov 2017 According to a Exicure media release, the company received authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) to conduct this trial in UK.
- 16 Oct 2017 Planned End Date changed from 1 Apr 2018 to 31 Aug 2018.
- 16 Oct 2017 Planned primary completion date changed from 28 Feb 2018 to 30 Jun 2018.